Johns Hopkins logo

Health Newsfeed

BREAST CANCER DRUGS

ANCHOR LEAD:   WHICH OF TWO MAJOR MEDICATIONS TO PREVENT BREAST CANCER RECURRENCE IS BETTER? ELIZABETH TRACEY REPORTS

Tamoxifen was the gold standard for women with certain types of breast cancer for preventing recurrence, then aromatase inhibitors came on the scene.  Now researchers are assessing the role of each in preventing recurrence.  Ben Park, a breast cancer expert at Johns Hopkins, says a recent study in the New England Journal of Medicine has an obvious conclusion.

PARK:  This is that sole therapy with one of these aromatase inhibitors, letrozole alone or in sequence with tamoxifen, doesn’t really have that big of a difference if you just use letrozole alone or an aromatase inhibitor alone, so that’s the gist of this is that we know right now that these aromatase inhibitors are  superior when compared head to head with tamoxifen for preventing recurrence of breast cancer and that women who seemed to sequence between the two weren’t necessarily going to get any additional benefit from doing it that way.              :30

Park adds that optimal duration of treatment with aromatase inhibitors is still under investigation.  At Johns Hopkins, I’m Elizabeth Tracey.


Search Health NewsFeed

-----------------------------------------
Health NewsFeed Home | Hopkins Medicine Home